Rol actual de la quimioterapia en cáncer de urotelio tras fracaso a platinos

45 / 66

Single Baseline Characteristics by OS With Nivolumab
CheckMate 057: Nivolumab vs Docetaxel in Previously Treated NSQ NSCLC
0
10
20
30
40
50
60
70
80
90
100
Patients with factor in
OS subgroup (%)
OS ≤3 months OS >3 months
<3 mo
from last
TX
PD
best
resp.
No maint.
TX
>5 sites
with lesions
Bone
mets
Liver
mets
Never Current/
former
0 1 <1% ≥1% ≥5% ≥10%
EGFR
mut.-pos.
Prior
therapy
Smoking
status
Baseline
disease site
PD-L1
expressiona
ECOG
PS
WCLC 2016; Abstract OA03.05 – Peters S